AMLX
USDAmylyx Pharmaceuticals Inc. Common Stock
$8.340+0.050 (0.603%)
Real-time Price
Healthcare
Biotechnology
United States
Price Chart
Loading Chart...
Key Metrics
Market Metrics
Open
$8.290
High
$8.590
Low
$8.210
Volume
1.68M
Company Fundamentals
Market Cap
743.4M
Industry
Biotechnology
Country
United States
Trading Stats
Avg Volume
1.44M
Exchange
NMS
Currency
USD
52-Week Range
Low $1.76Current $8.340High $8.59
Related News
BusinessWire
Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025
- Pivotal Phase 3 LUCIDITY trial of avexitide, a potential first-in-class GLP-1 receptor antagonist with FDA Breakthrough Therapy designation, underway in post-bariatric hypoglycemia; completion of recruitment expected
View more
Analyst Upgrades
Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market
Guggenheim initiates Amylyx at Buy with $17 price forecast, citing PBH drug avexitide's Phase 3 potential and $2 billion+ market opportunity.
View more
Analyst Upgrades
Guggenheim Initiates Coverage On Amylyx Pharmaceuticals with Buy Rating, Announces Price Target of $17
Guggenheim analyst Seamus Fernandez initiates coverage on Amylyx Pharmaceuticals with a Buy rating and announces Price Target of $17.
View more
Related Stocks
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.